The development of foveolar-type gastric adenocarcinoma during maintenance therapy of vonoprazan for reflux esophagitis

Research output: Contribution to journalArticlepeer-review

Abstract

We herein report the first case of foveolar-type gastric adenocarcinoma that developed after the initiation of vonoprazan (VPZ). A 51-year-old man had heartburn at the first visit and reflux esophagitis endoscopically, so he started taking VPZ. An approximately 5-mm-sized reddish polyp with a raspberry-like morphology was detected at the anterior wall of the upper body of the stomach 156 weeks after starting maintenance therapy with VPZ 10 mg/day. It was diagnosed as foveolar-type gastric adenocarcinoma based on a biopsy. Another approximately 4-mm-sized foveolar-type gastric adenocarcinoma was also detected at the posterior wall of the middle body of the stomach.

Original languageEnglish
Pages (from-to)391-396
Number of pages6
JournalInternal Medicine
Volume60
Issue number3
DOIs
Publication statusPublished - 2021 Feb 1

Keywords

  • Foveolar-type gastric adenocarcinoma
  • Potassium-competitive acid blocker (P-CAB)
  • Serum gastrin
  • Vonoprazan (VPZ)

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'The development of foveolar-type gastric adenocarcinoma during maintenance therapy of vonoprazan for reflux esophagitis'. Together they form a unique fingerprint.

Cite this